Cubist Systematic Strategies’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Cubist Systematic Strategies’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-137,794	Closed	-$828K	–	4839
2022 Q4	$828K	Sell	137,794 -126,162	-48%	-$689K	﹤0.01%	2623
2022 Q3	$1.54M	Buy	263,956 +200,133	+314%	+$1.25M	0.01%	2251
2022 Q2	$381K	Sell	63,823 -467,777	-88%	-$2.4M	﹤0.01%	3270
2022 Q1	$2.48M	Buy	+531,600	New	+$1.59M	0.02%	1304
2021 Q4	–	Sell	-18,203	Closed	-$54K	–	3777
2021 Q3	$54K	Sell	18,203 -33,084	-65%	-$90.1K	﹤0.01%	2831
2021 Q2	$128K	Buy	51,287 +26,266	+105%	+$63K	﹤0.01%	2685
2021 Q1	$73K	Buy	+25,021	New	+$81.7K	﹤0.01%	2695
2015 Q2	–	Sell	-3,168	Closed	-$57K	–	2280
2015 Q1	$57K	Buy	+3,168	New	+$71.3K	﹤0.01%	1741
2014 Q3	–	Sell	-2,760	Closed	-$78K	–	2030
2014 Q2	$78K	Buy	+2,760	New	+$82.9K	﹤0.01%	1360

Other funds holding CTIC

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Cubist Systematic Strategies's CTIC Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 137,794 shares — an estimated $828K sold.

Cubist Systematic Strategies first reported a position in CTIC in Q2 2014 and held it in 9 quarters. The position peaked at $2.48M in Q1 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

Cubist Systematic Strategies reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
Cubist Systematic Strategies sold 137,794 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $828K.
Cubist Systematic Strategies first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2014 and held it in 9 quarters.
Cubist Systematic Strategies's CTI BioPharma Corp. (DE) Common Stock position peaked at $2.48M in Q1 2022.
133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.